SLC6A17: A Potential Drug Target and Neurotransmitter Transporter

Target Name: SLC6A17

NCBI ID: G388662

SLC6A17

SLC6A17: A Potential Drug Target and Neurotransmitter Transporter

SLC6A17, also known as SLC6A17, is a member of the Solute Carrier Family 6 (SCF6) and is located on the protein known as SLC6A17. It is a transmembrane protein that is expressed in various tissues, including the brain, and is involved in the transport of various neurotransmitters. SLC6A17 has been identified as a potential drug target and may serve as a biomarker for various neurological disorders.

The SLC6A17 gene is located on chromosome 12 and encodes a protein that is composed of 188 amino acids. The protein has a calculated molecular weight of 21.4 kDa and a calculated pI of 9.97. SLC6A17 is predominantly expressed in the brain and is also found in other tissues, including the heart, skeletal muscles, and pancreas.

SLC6A17 is involved in the transport of various neurotransmitters, including dopamine, serotonin, and neurotensin. These neurotransmitters play a crucial role in the function of the brain and are involved in a wide range of physiological processes, including mood regulation, appetite, and movement. The SLC6A17 protein is thought to be involved in the regulation of the availability of these neurotransmitters in the brain and may be a target for drugs that are designed to treat disorders related to neurotransmitter imbalances.

SLC6A17 has also been shown to be involved in the regulation of ion channels in the brain. The SLC6A17 protein is expressed in the brain and has been shown to be involved in the regulation of the ion channels that are responsible for the flow of ions into and out of the brain cells. This function is important for the proper functioning of the brain and may be related to a wide range of neurological disorders.

In addition to its involvement in neurotransmitter transport and ion channel regulation, SLC6A17 has also been shown to be involved in the regulation of various signaling pathways that are involved in the development and progression of neurological disorders. For example, SLC6A17 has been shown to be involved in the regulation of the androgen signaling pathway, which is involved in the development of prostate cancer. This suggests that SLC6A17 may be a potential drug target for prostate cancer.

SLC6A17 has also been shown to be involved in the regulation of the insulin signaling pathway, which is involved in the development and progression of type 2 diabetes. This suggests that SLC6A17 may be a potential drug target for type 2 diabetes.

In conclusion, SLC6A17 is a transmembrane protein that is involved in the transport of various neurotransmitters and in the regulation of ion channels and signaling pathways. As a result, SLC6A17 is a potential drug target and may serve as a biomarker for a wide range of neurological disorders. Further research is needed to fully understand the role of SLC6A17 in neurotransmission and to develop effective treatments for disorders related to its dysfunction.

Protein Name: Solute Carrier Family 6 Member 17

Functions: Functions as a sodium-dependent vesicular transporter selective for proline, glycine, leucine and alanine. In contrast to other members of this neurotransmitter transporter family, does not appear to be chloride-dependent (By similarity)

The "SLC6A17 Target / Biomarker Review Report" is a customizable review of hundreds up to thousends of related scientific research literature by AI technology, covering specific information about SLC6A17 comprehensively, including but not limited to:
•   general information;
•   protein structure and compound binding;
•   protein biological mechanisms;
•   its importance;
•   the target screening and validation;
•   expression level;
•   disease relevance;
•   drug resistance;
•   related combination drugs;
•   pharmacochemistry experiments;
•   related patent analysis;
•   advantages and risks of development, etc.
The report is helpful for project application, drug molecule design, research progress updates, publication of research papers, patent applications, etc. If you are interested to get a full version of this report, please feel free to contact us at BD@silexon.ai

More Common Targets